Records identified through database searching (n = 2,410)

Additional records identified through other sources (n = 0)

Records after duplicates removed (n = 1,840)

Records excluded (n = 1,751)
- not post menopausal women: 612
- not RCT vs placebo: 28
- not a drug study: 708
- not fracture study: 408

Records screened (n = 1,840)

Full-text articles assessed for eligibility (n = 89)

Full-text articles excluded, with reasons (n = 59)
- not post menopausal women: 9
- not RCT vs placebo 34
Other: 16
- abstract only (2), add-on therapies (1), extension studies (2), not enough data (9), longer study available (2)

Studies included in quantitative synthesis (meta-analysis) (n = 30)
- Alendronate 6
- Denosumab 1
- Etidronate 8
- Ibandronate 4
- Raloxifene 1
- Risedronate 6
- Strontium 2
- Teriparatide 1
- Zoledronate 1